Can you tell me psoriasis dose in cosentyx milligrams?

Starting Dosage and Frequency

The recommended starting dose of Cosentyx (secukinumab) for adults with moderate to severe plaque psoriasis is 300 milligrams (mg) administered subcutaneously at weeks 0, 1, 2, and 3, followed by 300 mg every 4 weeks. This dose can be initiated without a loading dose. [1]

Alternative Doses and Regimens

For patients weighing < 60 kg, an alternative dose of 150 mg every 4 weeks is recommended.

Dosage Changes and Adjustments

If there is a reduced efficacy, dose increases up to a maximum of 600 mg can be considered. However, dosage adjustments for inadequate response or lack of efficacy should be carefully managed under physician supervision.

Interactions and Contraindications

As with any biologic agent, patients with a history of inflammatory bowel disease (IBD), or those being treated with other therapies that might cause increased risk of IBD, should be closely monitored.

Cosentyx and Other Psoriasis Treatments

It is worth noting, the patent for Cosentyx [2] does not expire until mid-2032. However, the patent for biosimilars that replicate the active ingredient of this treatment has been filed by companies such as Amgen (Secukinumab-AzoE-AMD, also known as AMGEVITY [3]) and Pfizer (PF-06441991 [3]). This could potentially provide lower-cost alternatives in the near future.

Sources:

[1] DrugPatentWatch.com - Secukinumab (Cosentyx)
[2] DrugPatentWatch.com - Secukinumab (Cosentyx)
[3] DrugPatentWatch.com - AMGEVITY (Secukinumab- AzoE-AMD)